ALZCUR.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$174M	+334.8%	$-0.35	$-0.35–$-0.35	—	1
2027	$11M	-93.7%	$-0.53	$-0.53–$-0.53	—	1
2028	$73M	+563.6%	$-0.61	$-0.61–$-0.61	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

DCF fair valuemodel estimate

Intrinsic value

$0.45

Price

$8.00

Implied downside

-94%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ALZCUR.STAlzeCure Pharma AB	$7.96	-0.50%	$1.0B	—
ACUC.STAcuCort AB	$0.55	+3.00%	$129M	—
BOUL.STBoule Diagnostics AB	$2.58	-0.00%	$100M	—
ERMA.STEnorama Pharma AB (publ)	$0.71	-10.58%	$53M	—
IRLAB-A.STIRLAB Therapeutics AB (publ)	$1.84

AlzeCure Pharma AB

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.

www.alzecurepharma.se

Employees: 10
IPO / List date: Nov 28, 2018
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds ALZCUR.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ALZCUR.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ALZCUR.ST yet.